PipelBiz, an Israeli investment platform, backed Sirtlab’s progress toward human trials for an age-reversing drug claimed to extend lifespan by up to 30%, supporting innovative biomedical research with potential public health benefits.

In the wake of January 2018 regulatory reforms by the Knesset—which relaxed equity crowdfunding rules—PipelBiz became the first platform licensed by the Israel Securities Authority (ISA) to offer equity-based crowdfunding to all Israeli citizens. This move significantly opens up startup investment opportunities to a broader public, breaking the traditional monopoly of venture capitalists and accredited investors.